<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972799</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_9798_AUTOGRAFI</org_study_id>
    <secondary_id>2020-A01890-39</secondary_id>
    <nct_id>NCT04972799</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Autologous Fat Injection Into the Intersphincter Space in Fecal Incontinence: a Randomized, Placebo-controlled, Cross-over, Double-blind Trial</brief_title>
  <acronym>AUTOGRAFI</acronym>
  <official_title>AUTOGRAFI : Evaluation of the Efficacy and Safety of Autologous Fat Injection Into the Intersphincter Space in Fecal Incontinence: a Randomized, Placebo-controlled, Cross-over, Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fecal incontinence is frequent and has a significant impact on the quality of life of&#xD;
      individuals. Its therapeutic management is based primarily on transit regulation and&#xD;
      rehabilitation and secondarily on neuromodulation of the sacral roots. However, this strategy&#xD;
      is insufficient in more than one patient out of three. The patient and the clinician are&#xD;
      often at a loss and the therapeutic possibilities are limited to the use of evacuating enemas&#xD;
      and/or a colostomy.&#xD;
&#xD;
      The practice of autologous fat injections was initially developed in plastic surgery. The&#xD;
      studies that have evaluated the efficacy of autologous fat injections in fecal incontinence&#xD;
      in men are preliminary and old isolated observations. However, they have shown an improvement&#xD;
      in episodes of fecal incontinence and in sphincter parameters. In the field of proctology and&#xD;
      autologous fat injections, 2 recent small open studies have evaluated the efficacy and&#xD;
      morbidity of this therapy in the treatment of anal fistulas related to Crohn's disease.&#xD;
&#xD;
      The primary hypothesis of the work is that autografting adipose tissue into the&#xD;
      intersphincteric space can decrease episodes of fecal incontinence in patients with severe&#xD;
      fecal incontinence due to sphincter failure. The secondary hypotheses are that autograft of&#xD;
      adipose tissue in the intersphincter space improves resting anal pressures, is a&#xD;
      well-tolerated technique for patients, and may improve their quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of fecal incontinence events</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline in number of fecal incontinence events at 3 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Treatment/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment sequence at day 0 and placebo sequence at 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo sequence at day 0 and treatment sequence at 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>injection of autologous fat at Day 0 and injection of saline at 6 months</intervention_name>
    <description>injection into the intersphincter space</description>
    <arm_group_label>Treatment/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>injection of saline at Day 0 and injection of autologous fat at 6 months</intervention_name>
    <description>injection into the intersphincter space</description>
    <arm_group_label>Placebo/Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older&#xD;
&#xD;
          2. severe fecal incontinence characterized by at least one episode of weekly fecal&#xD;
             incontinence&#xD;
&#xD;
          3. failed rehabilitation and dietary management strategies&#xD;
&#xD;
          4. who have failed/contraindicated/refused sacral root neuromodulation (in the indication&#xD;
             of fecal incontinence)&#xD;
&#xD;
          5. having, for women of childbearing age, effective contraception throughout the study&#xD;
&#xD;
          6. having given free, informed and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. unable or unwilling to undergo follow-up or symptomatic evaluation&#xD;
&#xD;
          2. contraindication to general anesthesia&#xD;
&#xD;
          3. contraindication to metronidazole (hypersensitivity and wheat allergy)&#xD;
&#xD;
          4. significant pelvic static disorder&#xD;
&#xD;
          5. active anal suppuration&#xD;
&#xD;
          6. anal stenosis&#xD;
&#xD;
          7. externalized rectal prolapse&#xD;
&#xD;
          8. chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis)&#xD;
&#xD;
          9. on anticoagulants or antiaggregants&#xD;
&#xD;
         10. history of anal or rectal neoplasia&#xD;
&#xD;
         11. coagulation anomaly, curative anticoagulation&#xD;
&#xD;
         12. history of rectal surgery&#xD;
&#xD;
         13. history of pelvic radiotherapy&#xD;
&#xD;
         14. previous treatment with inert materials (hyaluronic acid, biosilicones, coaptitis) in&#xD;
             the 5 years preceding inclusion&#xD;
&#xD;
         15. allergy to lidocaine or contraindication to adrenaline&#xD;
&#xD;
         16. protected person (adult subject to legal protection (safeguard of justice,&#xD;
             curatorship, guardianship), person deprived of liberty, pregnant or breast-feeding&#xD;
             woman, minor)&#xD;
&#xD;
         17. participating in another interventional trial concurrently&#xD;
&#xD;
         18. not covered by a social security system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brochard Charlène</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mevel Nicolas</last_name>
    <phone>02 99 28 25 55</phone>
    <email>dri@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ganivet Anne</last_name>
    <phone>02 99 28 25 55</phone>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vénara Aurélien</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emilie Duchalais</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Brochard Charlène</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autograft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

